This study reveals that myristolyated Src can repress RAIU via PBF and highlights NMT1 as a potential therapeutic target for the induction of RAIU in breast tumours and the restoration of NIS function in thyroid cancer. Here, SLC5A5 is linked to breast neoplasm.